Abstract Library

#4323 The value of 68Ga-Exendin-4 PET/CT for benign and metastatic insulinoma

Introduction: Insulinoma is the most common functional pancreatic neuroendocrine tumour which is difficult to locate by conventional imaging. 68Ga-exendin-4 PET/CT is a promising technique for detecting benign insulinomas but is not definite for metastatic insulinomas.

Conference:

Presenting Author: Xu J

Authors: Xu J, Liang Y, Huang D, Chen J, Song S,

Keywords: insulinoma, 68Ga-exendin-4, PET/CT,

#3540 Preoperative diagnosis impact on surgical strategies and outcomes in patients with medullary thyroid carcinoma

Introduction: Due to the difficulties with cytological identification of medullary thyroid carcinoma (MTC), the correct diagnosis is obtained postoperatively in a significant subset of patients.

Conference:

Presenting Author: Oleinikov K

Authors: Oleinikov K, Yaakov E, Mizrachi A, Hirsch D, Hirshoren N,

Keywords: cytology, preoperative diagnosis, medullary thyroid carcinoma, surgery outcome,

#3380 Dose selection for paltusotine, a once daily oral nonpeptide, somatostatin receptor 2 ligand, for the treatment of patients with Carcinoid Syndrome (CS)

Introduction: Long-acting somatostatin receptor ligands (LA-SRLs) are first line therapy for neuroendocrine tumor (NET) syndromes including acromegaly and the carcinoid syndrome (CS). In acromegaly, two phase 2 studies (NCT 03789656 and 03792555) suggested that patients injected with SRLs can switch to once daily orally bioavailable paltusotine (CRN00808), a nonpeptide, small molecule, somatostatin type 2 (SST2) receptor ligand (SRL), while maintaining stable serum IGF-1 levels. However, CS patients may require higher doses of an orally administered drug due to maldigestion commonly associated with the syndrome or its treatment and the pharmacokinetics (clearance and volume of distribution) of paltusotine may differ between CS and acromegaly because of differences in metabolic capacity of the liver and body composition.

Conference:

Presenting Author:

Authors: Lagast H, Madan A, Metz D, Luo R, Struthers S,

Keywords: neuroendocrine tumor, carcinoid syndrome, paltusotine, somatostatine receptor ligand, dose-response, exposure-response,

#3304 Ga-68/Lu-177 octreotate theranostic paradigm in metastatic Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumor with poor survival and significant propensity for metastasising. MCC is normally characterised by an up-regulation of somatostatin receptors (SSTR) which introduces the possibility for a targeted treatment approach using peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lenzo N

Authors: Falzone N, Meyrick D, Lee B, Lenzo N,

Keywords: peptide receptor radionuclide therapy, Merkel cell carcinoma, Lu-177 octreotate, Ac-225 octreotate,

#1521 Metastatic Disease in Gastroenteropancreatic Neuroendocrine Cancer: Incidence, Treatment and Survival

Introduction: Data on patients with metastatic disease from GEP-NETs are rare.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Madani A

Authors: Madani A, Van Der Bilt J, Haak H, De Hingh I, Lemmens V,

Keywords: metastases, carcinoid, gastroenteropancreatic neuroendocrine tumors, GEP-NETs, NETs, frequency, treatment, prognosis, survival,